Trials / Completed
CompletedNCT05225207
A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants
A Study of Lenvatinib in Korean Unresectable Hepatocellular Carcinoma (uHCC) Patients as a Post-marketing Surveillance
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 658 (actual)
- Sponsor
- Eisai Korea Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to describe the following safety and the efficacy of Lenvima for the first-line treatment indication of participants with uHHC in the post marketing setting: (1) Serious adverse events and serious adverse drug reactions (2) Unexpected adverse events and adverse drug reactions not reflected in the precautions for use (3) Known adverse drug reactions (4) Non-serious adverse drug reactions (5) Other safety and efficacy related information.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Non-interventional | No intervention will be administered. |
Timeline
- Start date
- 2019-05-28
- Primary completion
- 2022-01-31
- Completion
- 2022-01-31
- First posted
- 2022-02-04
- Last updated
- 2023-01-09
Locations
42 sites across 1 country: South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05225207. Inclusion in this directory is not an endorsement.